Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

Who May Be Eligible (Plain English)

Who May Qualify: - Sickle cell disease SS or S-béta° thalassemia - Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome - Age \> 18 years old Who Should NOT Join This Trial: - Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome) - Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23 - Anti-platelets agents - Red blood cell exchange or transfusion \< 3 months Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Sickle cell disease SS or S-béta° thalassemia * Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome * Age \> 18 years old Exclusion Criteria: * Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome) * Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23 * Anti-platelets agents * Red blood cell exchange or transfusion \< 3 months

Locations (1)

CHU de Toulouse
Toulouse, France, France